Back to Search
Start Over
The evanescence and persistence of RBC alloantibodies in blood donors.
- Source :
- Transfusion; Apr2020, Vol. 60 Issue 4, p831-839, 9p, 1 Diagram, 4 Charts, 1 Graph
- Publication Year :
- 2020
-
Abstract
- <bold>Background: </bold>Blood donors represent a healthy population, whose red blood cell (RBC) alloantibody persistence or evanescence kinetics may differ from those of immunocompromised patients. A better understanding of the biologic factors impacting antibody persistence is warranted, as the presence of alloantibodies may impact donor health and the fate of the donated blood product.<bold>Methods: </bold>Donor/donation data collected from four US blood centers from 2012 to 2016 as part of the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) were analyzed. Clinically significant antibodies from blood donors with more than one donation who underwent at least one follow-up antibody screen after the initial antibody identification were included. Of 632,378 blood donors, 481 (128 males and 353 females) fit inclusion criteria.<bold>Results: </bold>Antibody screens detected 562 alloantibodies, with 368 of 562 (65%) of antibodies being persistently detected and with 194 of 562 (35%) becoming evanescent. Factors associated with antibody persistence included antibody specificity, detection at the first donation, reported history of transfusion, and detection of multiple antibodies concurrently. Anti-D, C, and Fya were most likely to persist, while anti-M, Jka , and S were most frequently evanescent.<bold>Conclusions: </bold>These data provide insight into variables impacting the duration of antibody detection, and they may also influence blood donor center policies regarding donor recruitment/acceptance. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00411132
- Volume :
- 60
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- Transfusion
- Publication Type :
- Academic Journal
- Accession number :
- 142582738
- Full Text :
- https://doi.org/10.1111/trf.15718